TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3816291
Drug: Trimoprostil 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimoprostil 0.125 mg
Study: 29174623
Drug: Nonsurgical and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsurgical and noninjection therapies
Study: 22001391
Drug: Tipifarnib (T)
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (T) 600 mg twice a day × 14 days, Etoposide (E) 100 mg days 1‐3 and 8‐10
Study: 22001391
Drug: Tipifarnib (T)
Normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tipifarnib (T) 400 mg twice a day × 14 days, Etoposide (E) 200 mg days 1‐3 and 8‐10
Study: 19848555
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg) plus one Cal+D tablet (500 mg calcium and 200 IU vitamin D) daily
Study: 19848555
Drug: CEE/MPA (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE/MPA (0.625 mg conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate) plus one Cal+D tablet daily
Study: 19848555
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (one Cal+D tablet only)
Study: 9527081
Drug: Intermittent transdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent transdermal nitroglycerin patches (0.4, 0.8, or 1.6 mg/hour)
Study: 2708843
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily dose of netilmicin
Study: 2708843
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily doses of netilmicin
Study: 24245707
Drug: One-session exposure
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-session exposure treatment (OST)
Study: 21042231
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of TDV at months 0, 3.5, and 12 (TDV-TDV-TDV)
Study: 21042231
Drug: 1 injection
Normalized name: vitamin K1 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 injection of yellow fever vaccine (YF) at month 0, and 2 injections of TDV at months 3.5 and 12 (YF-TDV-TDV)
Study: 21042231
Drug: 3 injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 injections of TDV
Study: 19296144
Drug: Before-breakfast dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before-breakfast dosing of risedronate 5 mg daily
Study: 19296144
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing of risedronate 5 mg daily (2 h before and 2 h after any food and drink other than plain water)
Study: 17134335
Drug: Web administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Web administration of social desirability questionnaires
Study: 17134335
Drug: Laboratory administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laboratory administration of social desirability questionnaires
Study: 17134335
Drug: Self-selected online
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected online administration of social desirability questionnaires
Study: 9060551
Drug: Amoxicillin (2,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (2,250 mg) + Omeprazole for 14 days
Study: 8154249
Drug: Biological salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological salt solution (control)
Study: 3097668
Drug: Oral danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral danazol
Study: 18996864
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement (ONS) containing glutamine, carbohydrates, and antioxidants
Study: 18996864
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplement (ONS)
Study: 18996864
Drug: Glutamine infusion
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine infusion alone
Study: 16872926
Drug: Implant-supported prostheses
Normalized name: LARYNGEAL PROSTHESIS,PROVOX #8273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported prostheses (IP)
Study: 16872926
Drug: Implants placed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Implants placed
Study: 11078457
Drug: Prolonged hypoglycemia
Normalized name: Drugs for treatment of hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Study: 11078457
Drug: Short-duration hypoglycemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 5 min)
Study: 11078457
Drug: Day 1
Normalized name: New Day 1.5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1 euglycemia (5.2 +/‐ 0.1 mmol/l)
Study: 11078457
Drug: Intermediate-duration hypoglycemia
Normalized name: Prevotella intermedia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate-duration hypoglycemia (2.9 +/‐ 0.1 mmol/l for 30 min)
Study: 10165528
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous (i.v.) antibacterial therapy
Study: 10165528
Drug: Abbreviated regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated regimen of intravenous antibacterials for 2 to 4 days followed by oral ciprofloxacin or oral enoxacin
Study: 25312446
Drug: Switch therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch therapy
Study: 7934684
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 150 micrograms/10 ml
Study: 3728446
Drug: Self-administered mailed
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered mailed questionnaire
Study: 27938990
Drug: Low-Energy Linear
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) once a week for 5 weeks
Study: 27938990
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment once a week for 5 weeks
Study: 27938990
Drug: Low-Energy Linear
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Energy Linear Shockwave Therapy (LLi‐ESWT) after a 4-week break, once a week for 5 weeks
Study: 27938990
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment after a 4-week break, once a week for 5 weeks
Study: 27938990
Drug: Low-Energy Linear
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Energy Linear Shockwave Therapy (LLi‐ESWT)
Study: 23862237
Drug: Compound Xuanju
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Xuanju Capsule + Tamsulosin Hydrochloride
Study: 23862237
Drug: Quinolinone antibiotics
Normalized name: quinoline yellow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinolinone antibiotics + Tamsulosin Hydrochloride
Study: 19558835
Drug: Local and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local and general dexamethasone administration
Study: 19558835
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone injection
Study: 16925616
Drug: Non-pharmacological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacological treatments
Study: 15191380
Drug: Albendazole 10
Normalized name: albendazole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 10 mg/kg for 5 days
Study: 15191380
Drug: Metronidazole 20
Normalized name: metronidazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 20 mg/kg daily in three doses for 7 days
Study: 11465638
Drug: 450 mg
Normalized name: aspirin 450 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg moclobemide during the first week, and 600 mg afterwards
Study: 9157942
Drug: 4 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d of eicosapentaenoic and docosahexaenoic acids (fish oil)
Study: 8354983
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment with beta blockers and diuretics for a mean follow-up of 25 months
Study: 3440385
Drug: 24 hours
Normalized name: PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 hours of oxygen administration
Study: 3440385
Drug: 12 hours
Normalized name: PATCH, TRANSDERMAL 12 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 hours of oxygen administration
Study: 26539982
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg∙kg‐1)
Study: 15825785
Drug: ibuprofen/ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen/ibuprofen
Study: 15825785
Drug: acetaminophen/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen/acetaminophen
Study: 15825785
Drug: aspirin/aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin/aspirin
Study: 12424402
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost (0.005%, once daily) for 30 days (monotherapy group)
Study: 12424402
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost (0.005%, once daily) for 180 days (combination treatment group)
Study: 8951927
Drug: Lornoxicam (4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (4, 8, 16 and 20 mg)
Study: 8951927
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 and 20 mg)
Study: 8951927
Drug: Lornoxicam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (4 mg)
Study: 8951927
Drug: Lornoxicam (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lornoxicam (all doses)
Study: 1657611
Drug: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at doses of 5, 10, 20, 50 and 100 mg
Study: 1657611
Drug: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17
Approvals — FDA: no, EMA: no, PMDA: no
Description: N‐(2‐methyl‐2‐propyl)‐3‐oxo‐4‐aza‐5 alpha‐androst‐1‐ene‐17 beta‐carboxamide (I) at 10 mg/d for 7 days
Study: 6942835
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g deanol per day
Study: 6942835
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g deanol per day
Study: 24898300
Drug: Albiglutide (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide (30 mg weekly, uptitrated to 50 mg if necessary)
Study: 24898300
Drug: Thrice-daily prandial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-daily prandial insulin lispro
Study: 22723322
Drug: Teriparatide (56.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (56.5 μg)
Study: 20369761
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus fentanyl 25 microg and a nitroglycerine patch (Group F-N)
Study: 20369761
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus fentanyl 25 microg and a placebo patch (Group F)
Study: 20369761
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus saline 0.5 ml and a nitroglycerine patch (Group B-N)
Study: 20369761
Drug: Bupivacaine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine plus saline 0.5 ml and a placebo patch (Group B)
Study: 17368339
Drug: sodium perborate
Normalized name: Sodium Perborate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium perborate + 30% hydrogen peroxide solution (SP + HP)
Study: 17368339
Drug: sodium perborate
Normalized name: Sodium Perborate
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium perborate + 2% chlorhexidine gel (SP + CHX)
Study: 17368339
Drug: 37% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% carbamide peroxide gel (CP)
Study: 17368339
Drug: 37% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 37% carbamide peroxide gel + 2% chlorhexidine gel (CP + CHX)
Study: 12426215
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein (minimum of 25 g animal protein or isolated soy protein/4.2 MJ)
Study: 12426215
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein in individuals with LDL cholesterol > or =4.14 mmol/L
Study: 12426215
Drug: Isoflavones (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoflavones (50 mg/4.2 MJ)
Study: 2045759
Drug: High intake
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High intake of vitamin-K-rich vegetables for 7 days (median daily vitamin K intake 1100 micrograms)
Study: 2045759
Drug: Phytomenadione supplementation
Normalized name: phytomenadione
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phytomenadione supplementation (1000 micrograms daily)
Study: 6992570
Drug: Carbenicillin plus
Normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbenicillin plus gentamicin (C-G)
Study: 6992570
Drug: Combined results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined results of C-G
Study: 6992570
Drug: C-G
Normalized name: IC-Green
DrugBank: Indocyanine green acid form (DB09374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-G
Study: 23721792
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis plus circumcision
Study: 23721792
Drug: Antibiotic prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prophylaxis only
Study: 17825687
Drug: P‐OM3 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐OM3 plus simvastatin 40 mg/d
Study: 17825687
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus simvastatin 40 mg/d
Study: 1654364
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of acyclovir five times daily for 10 days
Study: 1654364
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of acyclovir
Study: 23494593
Drug: Postoperative drainage
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative drainage for 5 days or drain removal when less than 50 mL/24 h
Study: 19182619
Drug: Circumferential negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential negative-pressure wound therapy at -400 mmHg
Study: 19182619
Drug: Circumferential negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential negative-pressure wound therapy at -125 mmHg
Study: 19182619
Drug: Noncircumferential negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncircumferential negative-pressure wound therapy at -400 mmHg
Study: 19182619
Drug: Noncircumferential negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncircumferential negative-pressure wound therapy at -125 mmHg
Study: 19182619
Drug: Circumferential negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential negative-pressure wound therapy at -400 mmHg vs -125 mmHg
Study: 19182619
Drug: Noncircumferential negative-pressure
Normalized name: DRESSING,NEGATIVE PRESSURE WOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncircumferential negative-pressure wound therapy at -400 mmHg vs -125 mmHg
Study: 11524060
Drug: Implanted cardioverter-defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implanted cardioverter-defibrillator therapy
Study: 9519950
Drug: Isoniazid (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (twice weekly for 24 weeks)
Study: 9519950
Drug: Rifampicin and
Normalized name: rifampicin and isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin and pyrazinamide (twice weekly for 8 weeks)
Study: 21367351
Drug: Quality pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality pharmacotherapy
Study: 21367351
Drug: Adequate dose
Normalized name: Adequan
DrugBank: Polysulfated glycosaminoglycan (DB11538)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adequate dose of antianxiety medication
Study: 21367351
Drug: Quality pharmacotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quality pharmacotherapy or psychotherapy
Study: 21367351
Drug: Both quality
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both quality pharmacotherapy and psychotherapy
Study: 18384466
Drug: Antidepressant drugs
Normalized name: MAO A Inhibitors, antidepressant drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant drugs (2-4 types) and other psychotropic drugs
Study: 18384466
Drug: Multiple antidepressants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple antidepressants, tricyclic antidepressants, hypnosedatives, lithium, and/or antipsychotics
Study: 11073508
Drug: Aspirin (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (doses below 163 mg/day)
Study: 11073508
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release formulations of aspirin
Study: 9339405
Drug: 7.5% hypertonic
Normalized name: SODIUM CHLORIDE 7.5 g in 100 mL ORAL LIQUID [7.5% Hypertonic Saline]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5% hypertonic saline solution (HS)
Study: 8439639
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine b.d.s. plus 10 mg metoclopramide q.d.s.
Study: 27863165
Drug: eHealth screening,
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth screening, brief intervention and referral to treatment (SBIRT)
Study: 30595143
Drug: Yoga group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga group (twice-weekly group classes and once-weekly home practice focused on Iyengar-based yoga techniques)
Study: 17122092
Drug: PACAP (4x12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PACAP (4x12.5 microg administered intravenously in a pulsatile fashion hourly between 2200 and 0100)
Study: 10447050
Drug: Lidocaine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine i.v. bolus (0.69 or 0.75 mg x kg(‐1)) under hyperbaric/hyperoxic conditions (HBO: 2.5 bar or 0.25 MPa)
Study: 10447050
Drug: Lidocaine i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine i.v. bolus (0.69 or 0.75 mg x kg(‐1)) under normobaric conditions (NB: 1 bar or 0.1 MPa, air)
Study: 2270529
Drug: Platelet aggregation
Normalized name: Platelet aggregation inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet aggregation (PA) measurements before treatment and yearly during a 3-year period
Study: 24648802
Drug: D-002 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-002 (50 mg/day)
Study: 23048011
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (triphasic estradiol and norethisterone acetate for women with intact uterus; 2 mg estradiol for women with hysterectomy)
Study: 18763287
Drug: H pylori
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: H pylori IgG antibodies
Study: 16249890
Drug: Intravenous immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulins (IVIg) at 0.75 g/kg/day for 5 days
Study: 16249890
Drug: Intravenous cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cyclosporin A (CsA) at 5 mg/kg/day for 5 days
Study: 8941008
Drug: Cyclophosphamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and cisplatin (standard therapy)
Study: 6373094
Drug: Cephalexin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1.0 g or 0.5 g daily on a bid regimen (30 mg/kg mean daily dose)
Study: 6373094
Drug: Cephalexin 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin 1.0 g or 0.5 g daily on a qid regimen (29 mg/kg mean daily dose)
Study: 29125702
Drug: PTL101 containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTL101 containing 10 mg CBD
Study: 29125702
Drug: PTL101 containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTL101 containing 100 mg CBD
Study: 29125702
Drug: Sativex oromucosal
Normalized name: Castanea sative leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sativex oromucosal spray (reference product)
Study: 1596595
Drug: Other classes
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other classes of drugs (vasodilators, antiplatelet drugs, anticoagulants, prostaglandins)
Study: 22541408
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (200 μg/d)
Study: 18251036
Drug: Long-term CS-based
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term CS-based regimen with no antibody induction (control group; n = 16)
Study: 15511603
Drug: Low-dose 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose 0.25 mg dexamethasone suppression test (LD-DST)
Study: 10630494
Drug: Clarithromycin (CLA)
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin (CLA) 250 mg
Study: 1934204
Drug: Indomethacin suppositories,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppositories, 100 mg q8hr for five doses
Study: 6130197
Drug: Cl2MDP 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cl2MDP 1600 mg/day orally
Study: 26946419
Drug: Ologen implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ologen implant (OLO)
Study: 16240703
Drug: Bimosiamose disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bimosiamose disodium 30 mg/kg